Eton Pharmaceuticals plans ASN-001 NDA submission in 2H 2027 after infantile hemangioma Phase II/III data
ETON•ASN-001 development timeline and trial results
Eton Pharmaceuticals licensed U.S. rights to late-stage ASN-001, a topical timolol gel for moderate superficial infantile hemangiomas.
Clinical results were already presented from a completed Phase II/III trial, showing better lesion clearance than placebo.
A bioavailability bridging study is planned to support an NDA filing in 2H 2027, targeting a 2028 launch.
Management flagged 20,000 to 30,000 potential annual patients, positioning ASN-001 as a possible top portfolio revenue driver.
